Cencora, Inc. (NYSE:COR) Shares Sold by Symmetry Partners LLC

Symmetry Partners LLC reduced its holdings in shares of Cencora, Inc. (NYSE:COR) by 87.2% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 895 shares of the company’s stock after selling 6,086 shares during the period. Symmetry Partners LLC’s holdings in Cencora were worth $202,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of COR. New Millennium Group LLC bought a new stake in shares of Cencora in the 2nd quarter valued at approximately $26,000. TCTC Holdings LLC bought a new stake in shares of Cencora during the 1st quarter valued at about $29,000. TFO Wealth Partners LLC acquired a new position in Cencora in the first quarter valued at approximately $30,000. LRI Investments LLC bought a new stake in shares of Cencora in the 1st quarter worth approximately $31,000. Finally, MFA Wealth Advisors LLC acquired a new position in Cencora during the 2nd quarter valued at approximately $30,000. Institutional investors own 97.52% of the company’s stock.

Insider Buying and Selling

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total value of $5,071,822.20. Following the transaction, the chairman now owns 285,088 shares in the company, valued at approximately $67,223,750.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of the company’s stock in a transaction dated Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the completion of the sale, the chairman now directly owns 285,088 shares of the company’s stock, valued at approximately $67,223,750.40. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Silvana Battaglia sold 1,473 shares of Cencora stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total transaction of $357,482.37. Following the completion of the transaction, the executive vice president now directly owns 10,948 shares in the company, valued at approximately $2,656,970.12. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 15.80% of the company’s stock.

Cencora Price Performance

Shares of COR traded up $6.19 during midday trading on Friday, reaching $234.27. The stock had a trading volume of 1,619,694 shares, compared to its average volume of 1,405,605. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.55. The company has a market capitalization of $46.16 billion, a P/E ratio of 25.44, a P/E/G ratio of 1.46 and a beta of 0.44. The firm’s 50 day moving average price is $231.39 and its 200-day moving average price is $230.71. Cencora, Inc. has a 52 week low of $184.00 and a 52 week high of $247.66.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share for the quarter, beating analysts’ consensus estimates of $3.18 by $0.16. The company had revenue of $74.20 billion during the quarter, compared to the consensus estimate of $73.32 billion. Cencora had a net margin of 0.65% and a return on equity of 266.60%. Cencora’s revenue was up 10.8% on a year-over-year basis. During the same period in the prior year, the company earned $2.92 EPS. On average, analysts forecast that Cencora, Inc. will post 13.64 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Leerink Partners reduced their price target on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a report on Monday, October 7th. Wells Fargo & Company raised their price target on shares of Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a research note on Thursday, August 1st. JPMorgan Chase & Co. boosted their price objective on Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 21st. Evercore ISI lowered their target price on Cencora from $270.00 to $250.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Finally, Bank of America reaffirmed a “neutral” rating and set a $245.00 target price (down previously from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $259.44.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.